MORGAN STANLEY PLC/CALL/MODERNA/97.5/0.1/20.12.24 Share Price

Warrant

DE000MB9KNQ1

Market Closed - Börse Stuttgart 20:50:21 05/07/2024 BST
2.98 EUR +0.34% Intraday chart for MORGAN STANLEY PLC/CALL/MODERNA/97.5/0.1/20.12.24
Current month-0.33%
1 month-49.75%
Date Price Change
05/07/24 2.98 +0.34%
04/07/24 2.97 +6.07%
03/07/24 2.8 -3.78%
02/07/24 2.91 +2.11%
01/07/24 2.85 -4.68%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 08:50 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying MODERNA, INC.
Issuer Morgan Stanley
WKN MB9KNQ
ISINDE000MB9KNQ1
Date issued 08/08/2023
Strike 97.5 $
Maturity 20/12/2024 (167 Days)
Parity 10 : 1
Emission price 3.53
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 7.18
Lowest since issue 0.79
Delta0.76x
Omega 2.769
Premium9.93x
Gearing3.63x
Moneyness 1.214
Difference Strike -20.82 $
Difference Strike %-21.35%
Spread 0.05
Spread %1.65%
Theoretical value 3.005
Implied Volatility 65.60 %
Total Loss Probability 39.42 %
Intrinsic value 1.921
Present value 1.084
Break even 130.07 €
Theta-0.04x
Vega0.02x
Rho0.02x

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
More about the company

Ratings for Moderna, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Moderna, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.3 USD
Average target price
145.9 USD
Spread / Average Target
+23.27%
Consensus